Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
Characteristics predicting reduced penetrance variants in the high-risk cancer predisposition gene TP53.
Fortuno C et al.
Hgg Advances, 2025
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.
Tarabini RF et al.
Scientific Reports, 2024
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2024
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
Lee K et al.
Scientific Reports, 2023
Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast.
Xu YJ et al.
Plos Genetics, 2023
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
Comprehensive mutational analysis of the checkpoint signaling function of Rpa1/Ssb1 in fission yeast.
Xu YJ et al.
Biorxiv : the Preprint Server for Biology, 2023
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.
Kar SP et al.
Nature Genetics, 2022
Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex.
Klonowska K et al.
The Journal of Clinical Investigation, 2022
A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database.
Pappula AL et al.
Cancers, 2021
TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Al Zoubi MS et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G et al.
Blood Advances, 2020
Clonal hematopoiesis and risk of acute myeloid leukemia.
Young AL et al.
Haematologica, 2019
Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D et al.
Virchows Archiv : an International Journal of Pathology, 2019
Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches.
Ellis HP et al.
Journal of Oncology, 2019
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2017
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection.
Shimizu T et al.
Gastroenterology, 2014
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Chen Z et al.
Journal of the American College of Surgeons, 2011
TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K et al.
Cancer Genetics and Cytogenetics, 2008
Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies.
Poley JW et al.
Cancer, 2007
Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library.
Shiraishi K et al.
The Journal of Biological Chemistry, 2004
Differentially expressed downstream genes in cells with normal or mutated p53.
Xu H et al.
Oncology Research, 2003